What happens when you take bergamot with statins?
Bergamot (Citrus bergamia) is a sour citrus fruit grown almost exclusively in Calabria, Italy. It is the source of bergamot essential oil, which gives Earl Grey tea its characteristic aroma, and of bergamot polyphenolic fraction (BPF), a concentrated supplement marketed for cardiovascular health and cholesterol management. Bergamot is also the namesake of bergamottin, the furanocoumarin first identified as a major CYP3A4 inhibitor in grapefruit juice.
Statins that depend on CYP3A4 for metabolism include simvastatin, atorvastatin, and lovastatin. When CYP3A4 in the intestinal wall is disabled by furanocoumarins, more drug survives first-pass absorption, plasma concentrations rise, and the risk of muscle injury (myopathy, rhabdomyolysis) increases.
Because bergamot contains bergamottin by definition, the chemistry predicts an interaction with CYP3A4-metabolized statins. Laboratory studies confirm that bergamot juice and bergamot oil inhibit CYP3A4 in vitro. The clinical question is whether typical real-world exposure, such as drinking Earl Grey tea or taking a BPF supplement, produces a meaningful rise in statin levels in humans.
Why is this important?
The interaction sits in a gray zone of uncertainty, and the gray zone matters because bergamot is increasingly marketed alongside statins, not as an alternative. Bergamot polyphenolic fraction supplements are widely promoted to people with elevated cholesterol, often with claims that they can replace or augment a statin. Some users take BPF and a statin together, with little awareness that bergamot contains the same furanocoumarin family as grapefruit.
Direct human pharmacokinetic studies of bergamot supplements with statins are limited, but the building blocks of the interaction are well-established:
- Bergamottin is a potent, irreversible CYP3A4 inhibitor that drives the grapefruit-statin interaction.
- Bergamot juice and oil contain bergamottin and related furanocoumarins, sometimes at higher concentrations than grapefruit.
- Statin AUC can rise 1.5 to 3-fold or more with grapefruit; a similar mechanism would predict at least a modest rise with concentrated bergamot.
The risk is dose-dependent. A cup of Earl Grey tea delivers a very small amount of bergamot oil and is unlikely to meaningfully inhibit CYP3A4 in most people. A daily 500 mg BPF supplement is a much larger and more sustained exposure. Heavy Earl Grey drinkers (multiple cups daily) sit somewhere in between.
There is also a separate issue with bergamot oil: high doses can cause hypokalemia (low potassium) due to its bergapten content, which has been reported to interact with diuretics and contribute to muscle cramping. This is independent of the CYP3A4 interaction but is relevant to overall safety with cardiovascular medications.
What should you do?
If you are taking a CYP3A4-dependent statin (simvastatin, atorvastatin, lovastatin), be cautious about concentrated bergamot products:
- Bergamot polyphenolic fraction (BPF) supplements marketed for cholesterol
- Bergamot juice or concentrate
- Bergamot essential oil taken internally (which is not recommended in general)
Moderate Earl Grey tea consumption (one or two cups daily) is unlikely to be a clinical problem, but heavy intake (four or more cups daily) may warrant discussion with your pharmacist, especially with simvastatin or lovastatin, which are the most sensitive to CYP3A4 inhibition.
If you are considering a BPF supplement for cholesterol management while already on a statin, talk to your prescriber first. There is genuine interest in whether bergamot polyphenols add cholesterol-lowering benefit on top of a statin, but the combination should be supervised, with monitoring for muscle symptoms and possibly a creatine kinase check after starting.
An alternative is to switch to a statin that is not CYP3A4-dependent. Pravastatin, rosuvastatin, and fluvastatin are metabolized by other pathways and are not affected by furanocoumarins. If bergamot is important to you, ask about a statin switch.
Watch for muscle pain, weakness, dark urine, or unusual fatigue, and report these symptoms promptly. These are warning signs of statin-related muscle injury regardless of cause.
Which specific products are affected?
This caution applies to simvastatin (Zocor), atorvastatin (Lipitor), and lovastatin (Mevacor), the statins metabolized via CYP3A4. Other CYP3A4-dependent cardiovascular drugs (felodipine, amlodipine, amiodarone) and immunosuppressants (cyclosporine, tacrolimus, sirolimus) may also interact with concentrated bergamot products.
On the bergamot side, the products of concern are concentrated polyphenol supplements (often labeled BPF or bergamot extract, sold under brand names like Bergamonte), bergamot juice, and high-volume Earl Grey tea consumption. Bergamot in cosmetics and aromatherapy is not relevant; the issue is internal exposure.
The bottom line
Bergamot is the original source of bergamottin, the prototype furanocoumarin behind the grapefruit-drug interaction. While direct human studies of bergamot supplements with statins are limited, the chemistry strongly suggests that concentrated bergamot polyphenolic fraction products, bergamot juice, and heavy Earl Grey tea drinking can inhibit CYP3A4 and raise levels of simvastatin, atorvastatin, and lovastatin. Moderate Earl Grey tea is likely fine; a daily BPF supplement is not without question. If you want to combine bergamot with a statin, discuss it with your prescriber, or switch to pravastatin, rosuvastatin, or fluvastatin, which are not CYP3A4-dependent.